Literature DB >> 25285994

Evaluation of an oral supplement containing Phyllanthus emblica fruit extracts, vitamin E, and carotenoids in vitiligo treatment.

Roberta Colucci1, Federica Dragoni, Rossana Conti, Lisa Pisaneschi, Linda Lazzeri, Silvia Moretti.   

Abstract

Phyllanthus emblica, vitamin E, and caroteinods are compounds showing antioxidative, anti-inflammatory, and repigmenting effects, whose role in vitiligo treatment has not been evaluated so far. Sixty-five subjects (group A) were treated with one tablet of an oral supplement containing P. emblica (100 mg), vitamin E (10 mg), and carotenoids (4.7 mg) three times/day for 6 months and compared with a control group (group B, 65 patients), which instead was not treated with antioxidants. Both groups were simultaneously treated with a comparable topical therapy and/or phototherapy. After a 6 months follow-up, a significantly higher number of patients in group A had a mild repigmentation on the head/neck regions (p = 0.019) and on the trunk (trend, p = 0.051). The number of patients who presented no repigmentation in head/neck, trunk, upper, and lower limbs was significantly higher in group B (respectively, p = 0.009, p = 0.001, p = 0.001, p = 0.025). Moreover, group B patients showed higher signs of inflammation (p = 0.002), a more rapid growth of the lesions (p = 0.039), a higher percentage of worsening disease (p = 0.003), and more erythema (p = 0.059), whereas group A patients showed a higher percentage of steady disease (p = 0.065). Our results suggest that the supplement with antioxidants in patients with vitiligo might represent a valuable instrument to increase the effectiveness of other vitiligo treatments. [Correction added after online publication 06-Oct-2014: the dosages of vitamin E and carotenoids have been updated.].
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  antioxidants; vitiligo

Mesh:

Substances:

Year:  2014        PMID: 25285994     DOI: 10.1111/dth.12172

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  8 in total

Review 1.  Oxidative stress and immune system in vitiligo and thyroid diseases.

Authors:  Roberta Colucci; Federica Dragoni; Silvia Moretti
Journal:  Oxid Med Cell Longev       Date:  2015-03-09       Impact factor: 6.543

Review 2.  Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo.

Authors:  Ming-Chen Sun; Xiao-Ling Xu; Xue-Fang Lou; Yong-Zhong Du
Journal:  Int J Nanomedicine       Date:  2020-05-08

Review 3.  The Safety of Medicinal Plants Used in the Treatment of Vitiligo and Hypermelanosis: A Systematic Review of Use and Reports of Harm.

Authors:  Irshad Hussain
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-03-23

Review 4.  The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.

Authors:  Shan He; Jinhua Xu; Jinfeng Wu
Journal:  Oxid Med Cell Longev       Date:  2022-01-19       Impact factor: 6.543

5.  Serum vitamin E levels and chronic inflammatory skin diseases: A systematic review and meta-analysis.

Authors:  Xiaofang Liu; Guang Yang; Mengxin Luo; Qi Lan; Xiaoxia Shi; Haoyuan Deng; Ningning Wang; Xuezhu Xu; Cong Zhang
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

6.  The Current Status of Antioxidants in the Treatment of Vitiligo in China.

Authors:  Ying Zhou; Manal Khan; Ling Jiang; Chuhan Fu; Yumeng Dong; Liping Luo; Haoran Guo; Lijuan Gao; Xinxin Lei; Li Zhang; Xing Yu; Li Lei; Jinhua Huang; Jing Chen; Qinghai Zeng
Journal:  Oxid Med Cell Longev       Date:  2022-02-24       Impact factor: 6.543

Review 7.  Diet and Vitiligo: The Story So Far.

Authors:  Rajoshee R Dutta; Tanishq Kumar; Nishikant Ingole
Journal:  Cureus       Date:  2022-08-28

8.  Anti-inflammatory Effects of Phyllanthus emblica L on Benzopyrene-Induced Precancerous Lung Lesion by Regulating the IL-1β/miR-101/Lin28B Signaling Pathway.

Authors:  Cheng-Cheng Wang; Jia-Rui Yuan; Chun-Fei Wang; Nan Yang; Juan Chen; Dan Liu; Jie Song; Liang Feng; Xiao-Bin Tan; Xiao-Bin Jia
Journal:  Integr Cancer Ther       Date:  2016-08-24       Impact factor: 3.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.